Jiajie Chen

Dr. Jiajie Chen

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HWHui-Na Wang
Hui-Na Wang
KJkunmei Ji
kunmei Ji
LZLi-Na Zhang
Li-Na Zhang
CXChuchu Xie
Chuchu Xie
WLWei-Yong Li
Wei-Yong Li
JCJiajie Chen
Jiajie Chen
Background: Activator protein-1 (AP1), a c-Fos–JUN transcription factor complex, mediates many cytobiological processes. c-Fos has been implicated in immunoglobulin (Ig)E activation of mast cells (MCs) via high-affinity IgE Fc receptor (FcεRI) binding. This study examined c-Fos involvement in MC activation and tested the effects of the c-Fos/AP1 inhibitor T-5224 on MCs activation and allergic responses. Methods: In vitro studies were conducted with two MC model systems: rat basophilic leukemia cells (RBLs) and mouse bone marrow derived mast cells (BMMCs). MC degranulation and effector functions were examined with β-hexosaminidase release and cytokine secretion assays. c-Fos/AP1 was inhibited with T-5224. c-Fos activity was suppressed with short hairpin RNA targeting c-Fos (shFos). In vivo immune responses were evaluated in passive cutaneous anaphylaxis (PCA) and ovalbumin-induced active systemic anaphylaxis (ASA) models, as well as in an oxazolone (OXA)-induced model of atopic dermatitis, a common allergic disease. Results: c-Fos expression was elevated transcriptionally and translationally in IgE-stimulated MCs. c-Fos binding of the Egr1 (early growth response 1) promoter upregulated Egr1 transcription, leading to production of interleukin (IL)4. T-5224 reduced FcεRI-mediated MC degranulation (evidenced by β-hexosaminidase activity and histamine levels) and diminished EGR1 and IL4 expression. T-5224 attenuated IgE-mediated allergic responses in PCA and ASA models, and it suppressed MC-mediated atopic dermatitis in mice. Conclusion: IgE binding can activate MCs via a c-Fos/Egr1/IL-4 axis. T-5224 suppresses MC activation in vitro and in vivo and thus represents a promising potential strategy for targeting MC activation to treat allergic diseases.

8 February 2019 in Brain Imaging and Behavior
Verified
Journal Article
Closed access
PDF file
XWXuan Wei
Xuan Wei
WLWei Li
Wei Li
JCJiajie Chen
Jiajie Chen
YLYongbin Li
Yongbin Li
JZJia Zhu
Jia Zhu
WWWei Wang
Wei Wang

1 October 2021 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JCJiajie Chen
Jiajie Chen
LZLi-Na Zhang
Li-Na Zhang
HWHui-Na Wang
Hui-Na Wang
CXChu-Chu Xie
Chu-Chu Xie
WLWei-Yong Li
Wei-Yong Li
KJkunmei Ji
kunmei Ji

4 February 2020 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
LZLi‐Na Zhang
Li‐Na Zhang
KJkunmei Ji
kunmei Ji
YSYue‐Tong Sun
Yue‐Tong Sun
YHYi‐Bo Hou
Yi‐Bo Hou
JCJiajie Chen
Jiajie Chen

7 July 2023 in Molecules
Verified
Journal Article
Open access
PDF file
ZZZi-Wen Zhou
Zi-Wen Zhou
XZXue-Yan Zhu Zhu
Xue-Yan Zhu Zhu
SLShu-Ying Li
Shu-Ying Li
SLSien Lin
Sien Lin
YZYu-Han Zhu
Yu-Han Zhu
JCJiajie Chen
Jiajie Chen
Formononetin (FNT) is a plant-derived isoflavone natural product with anti-inflammatory, antioxidant, and anti-allergic properties. We showed previously that FNT inhibits immunoglobulin E (IgE)-dependent mast cell (MC) activation, but the effect of FNT on IgE-independent MC activation is yet unknown. Our aim was to investigate the effects and possible mechanisms of action of FNT on IgE-independent MC activation and pseudoallergic inflammation. We studied the effects of FNT on MC degranulation in vitro with a cell culture model using compound C48/80 to stimulate either mouse bone marrow-derived mast cells (BMMCs) or RBL-2H3 cells. We subsequently measured β-hexosaminase and histamine release, the expression of inflammatory factors, cell morphological changes, and changes in NF-κB signaling. We also studied the effects of FNT in several in vivo murine models of allergic reaction: C48/80-mediated passive cutaneous anaphylaxis (PCA), active systemic anaphylaxis (ASA), and 2,4-dinitrobenzene (DNCB)-induced atopic dermatitis (AD). The results showed that FNT inhibited IgE-independent degranulation of MCs, evaluated by a decrease in the release of β-hexosaminase and histamine and a decreased expression of inflammatory factors. Additionally, FNT reduced cytomorphological elongation and F-actin reorganization and attenuated NF-κB p65 phosphorylation and NF-κB-dependent promoter activity. Moreover, the administration of FNT alleviated pseudoallergic responses in vivo in mouse models of C48/80-stimulated PCA and ASA, and DNCB-induced AD. In conclusion, we suggest that FNT may be a novel anti-allergic drug with great potential to alleviate pseudoallergic responses via the inhibition of IgE-independent MC degranulation and NF-κB signaling.

25 February 2022 in Food & Function
Verified
Journal Article
Closed access
PDF file
CXChuchu Xie
Chuchu Xie
BZBo-Ping Zhang
Bo-Ping Zhang
HWHui-Na Wang
Hui-Na Wang
WLWei-Yong Li
Wei-Yong Li
ZCZe-Lang Cai
Ze-Lang Cai
JCJiajie Chen
Jiajie Chen
Mast cells (MCs) are the main effector cells in the onset of high-affinity receptor for IgE (FcεRI)-mediated allergic diseases. The aim of this study was to test whether dihydrocoumarin (DHC), a food flavoring agent derived from Melilotus officinalis, can block IgE-induced MC activation effects and to examine the potential molecular mechanisms by which DHC affects MC activation. Rat basophilic leukemia cells (RBLs) and mouse bone marrow-derived mast cells (BMMCs) were sensitized with anti-dinitrophenol (DNP) immunoglobulin (Ig)E antibodies, stimulated with DNP-human serum albumin antigen, and treated with DHC. Western blot analyses were performed to detect the expression of signaling proteins. Murine IgE-mediated passive cutaneous anaphylaxis (PCA) and ovalbumin (OVA)-induced active systemic anaphylaxis (ASA) models were used to examine DHC effects on allergic reactions in vivo. DHC inhibited MC degranulation, as evidenced by reduced β-hexosaminidase activity and histamine levels, and reduced morphological changes associated with MC activation, namely cellular elongation and F-actin reorganization. DHC inhibited the activation of MAPK, NF-κB, and AP-1 pathways in IgE-activated MCs. Additionally, DHC could attenuate IgE/Ag-induced allergic reactions (dye extravasation and ear thickening) in PCA as well as OVA challenge-induced reactions in ASA mice (body temperature, serum histamine and IL-4 secretion changes). In conclusion, DHC suppressed MC activation. DHC may represent a new MC-suppressing treatment strategy for the treatment of IgE-mediated allergic diseases.